Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
NCT ID: NCT07306988
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
120 participants
INTERVENTIONAL
2025-04-17
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Sponsor: Nanjing First Hospital Principal Investigator: Dr. Wanli Liu Department: Gastroenterology Study Duration: February 2025 - August 2025
Key Information for Patients and Families
1. What is this study about? This study aims to understand how treating a common stomach infection caused by Helicobacter pylori (Hp) might improve metabolic health issues like high blood sugar, cholesterol problems, or obesity (collectively called metabolic syndrome). Specifically, it explores whether adding probiotics (good bacteria) or a natural compound called berberine (BBR) to standard Hp treatment can enhance these benefits by improving gut bacteria balance.
2. Who can participate? Patients: Adults aged 18-65 with both Helicobacter pylori infection (confirmed by a breath test) and newly diagnosed metabolic syndrome (based on waist size, blood sugar, cholesterol, or blood pressure).
Healthy Volunteers: Adults aged 18-65 with no Hp infection and normal metabolic health (to compare results).
Exclusions:
Allergy to study medications (e.g., penicillin).
Previous Hp treatment, recent antibiotic/steroid use, pregnancy, or serious medical conditions (e.g., liver/kidney disease).
3. What will participants do?
Treatment Groups:
Group A: Take two medications (vonoprazan + amoxicillin) for 14 days.
Group B: Take the two medications + probiotics (Bifidobacterium tablets).
Group C: Take the two medications + berberine (a plant-based supplement).
Tests:
Before treatment: Breath test, blood tests (blood sugar, cholesterol, inflammation markers), stool sample analysis (gut bacteria), and body measurements (weight, waist size).
After treatment (1 month): Repeat tests to check Hp eradication and metabolic improvements.
4. Possible Benefits and Risks
Benefits:
Free Hp treatment and metabolic health monitoring.
Potential improvement in blood sugar, cholesterol, or weight.
Contribution to future treatments for metabolic syndrome.
Risks:
Mild side effects (e.g., nausea, diarrhea, stomach pain) from medications.
Discomfort from blood draws or stool sample collection.
5. How are participants protected? All treatments are FDA-approved or widely used in clinical practice.
Ethical review ensures participant safety.
You can withdraw at any time without affecting your regular care.
Information for Health Care Providers
1. Study Design Type: Prospective, single-center, open-label, randomized controlled trial.
Population: 140 participants (120 Hp+ patients with metabolic syndrome; 20 Hp- healthy controls).
Intervention:
Group A: Vonoprazan (20 mg bid) + amoxicillin (1 g tid) for 14 days.
Group B: Group A + Bifidobacterium tetragenous probiotic (3 tablets tid).
Group C: Group A + berberine (3 tablets tid).
Primary Outcomes:
Hp eradication rate (confirmed by urea breath test).
Changes in metabolic parameters (fasting glucose, HbA1c, lipid profile).
Gut microbiota composition (16S rRNA sequencing).
Secondary Outcomes:
Multi-omics analysis (inflammation markers, endotoxins, short-chain fatty acids, bile acids).
2. Scientific Rationale Hp and Metabolic Syndrome: Epidemiological evidence links Hp infection to metabolic dysfunction, possibly via chronic inflammation. Eradication may partially reverse insulin resistance and dyslipidemia.
Gut Microbiota as Mediator: Hp eradication alters gut microbiota, which regulates metabolic homeostasis through metabolites (e.g., SCFAs), bile acid metabolism, and inflammatory pathways. Probiotics/BBR may enhance these effects.
3. Methodology Randomization: Block randomization (block size = 4) using SAS 9.4.
Assessments:
Metabolic Parameters: Fasting glucose, HbA1c, lipid profile, BMI.
Microbiome: 16S rRNA sequencing (α/β diversity, taxa abundance).
Multi-omics: ELISA (TNF-α, IL-6), GC-MS (SCFAs), UPLC-MS (bile acids).
Statistical Analysis:
Microbiome: QIIME2, LEfSe, PICRUSt2.
Multi-omics: limma, SparCC, sPLS-DA.
Clinical data: ANOVA, χ² tests (SPSS v25.0).
4. Clinical Implications Clarify whether probiotics or BBR add value to Hp eradication in improving metabolic health.
Identify gut microbiota-driven mechanisms linking Hp eradication to metabolic benefits.
Resources for Participants
Study Flowchart:
Screening: Breath test, blood/stool tests (1 week).
Treatment: 14 days of medication.
Follow-up: Repeat tests at 1 month.
Contact Information:
Dr. Wanli Liu: +86-18951670222
Nanjing First Hospital Gastroenterology Department.
FAQ Sheet:
Can I take my regular medications? Yes, unless they interfere with Hp treatment (e.g., PPIs).
What if I miss a dose? Contact the study team immediately.
Ethical Compliance Approved by the Institutional Review Board of Nanjing First Hospital.
Complies with the Declaration of Helsinki and China's ethical guidelines.
Informed consent required for participation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VA group
Vonoprazan-Amoxicillin Dual Therapy
Patients receive oral vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily for 14 days. This regimen is a standard dual therapy for Helicobacter pylori eradication.
Probiotics Group
Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae
Patients receive oral vonoprazan 20 mg twice daily, amoxicillin 1000 mg three times daily, and Bifidobacterium tetravaccae probiotic tablets (3 tablets three times daily) for 14 days.
BBR Group
Vonoprazan-Amoxicillin with Berberine
Patients receive oral vonoprazan 20 mg twice daily, amoxicillin 1000 mg three times daily, and berberine hydrochloride tablets (3 tablets three times daily) for 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vonoprazan-Amoxicillin Dual Therapy
Patients receive oral vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily for 14 days. This regimen is a standard dual therapy for Helicobacter pylori eradication.
Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae
Patients receive oral vonoprazan 20 mg twice daily, amoxicillin 1000 mg three times daily, and Bifidobacterium tetravaccae probiotic tablets (3 tablets three times daily) for 14 days.
Vonoprazan-Amoxicillin with Berberine
Patients receive oral vonoprazan 20 mg twice daily, amoxicillin 1000 mg three times daily, and berberine hydrochloride tablets (3 tablets three times daily) for 14 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Aged 18-65 years;
2. Confirmed H. pylori-positive status by urea breath test (UBT), with no prior eradication therapy;
3. Newly diagnosed MS according to the Chinese Diabetes Society (CDS, 2004 Chinese criteria) ;
4. Voluntarily join the trial and sign informed consent.
* For H. pylori-negative healthy controls with normal metabolism:
1. Aged 18-65 years;
2. Confirmed H. pylori-negative status by UBT;
3. Normal metabolic parameters (e.g., blood glucose, lipid profile, blood pressure) without MS;
4. Voluntarily join the trial and sign informed consent.
Exclusion Criteria
2. Active peptic ulcer confirmed by endoscopy;
3. Prior history of H. pylori eradication therapy;
4. Use of medications for metabolic regulation (e.g., hypoglycemic agents, lipid-lowering drugs, weight-loss drugs)
5. Recent use of antibiotics or bismuth (within 4 weeks) or H2-receptor antagonists/PPIs (within 2 weeks) before enrollment;
6. Current use of corticosteroids, NSAIDs, or anticoagulants;
7. History of esophageal or gastric surgery;
8. Pregnant or breastfeeding women;
9. Severe comorbidities (e.g., hepatic, cardiovascular, pulmonary, renal diseases, inflammatory bowel disease);
10. Chronic alcohol abuse (\>40 g/day for men, \>20 g/day for women);
11. Malignancies (e.g., gastric mucosa-associated lymphoid tissue \[MALT\] lymphoma).
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ruolin Peng
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20250327-12
Identifier Type: -
Identifier Source: org_study_id